Jonathan Davis, MD
Cardiovascular Disease · Shreveport, LANPI 1801079330
Payments from drug & device makers
Across 200 payments — averaging $34.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$749
- Abiomed$735
- Pfizer$474
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$376
- Shockwave Medical, Inc$340
- plus $2K from 26 others
What the payments were for
- Travel & lodging$1,87327%
- Food & beverage$5,03273%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $2,325 |
| Medtronic(2 entities) | 12 | $749 |
| Abiomed | 24 | $735 |
| Pfizer | 31 | $474 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $376 |
| Shockwave Medical, Inc | 27 | $340 |
| Boston Scientific | 13 | $329 |
| Penumbra, Inc. | 2 | $239 |
| Novartis | 3 | $233 |
| Amarin Pharma, Inc. | 1 | $125 |
| Edwards Lifesciences | 1 | $121 |
| Itamar Medical Inc | 3 | $113 |
| E.r. Squibb & Sons, L.L.C. | 6 | $87 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $68 |
| Merck | 4 | $61 |
| Actelion Pharmaceuticals US, Inc. | 3 | $55 |
| Boehringer Ingelheim | 4 | $54 |
| Novo Nordisk | 3 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Recor Medical Inc | 2 | $45 |
| Cvrx, Inc. | 2 | $38 |
| Bayer | 2 | $33 |
| Astellas Pharma US Inc | 2 | $30 |
| Philips North America LLC | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| AstraZeneca | 1 | $24 |
| Chiesi USA, Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIENCE SKYPOINT$2,078
- Indigo System$239
- FFRangio$216
- Impella$146
- Vascepa$125
- COREVALVE EVOLUT R$123
- Edwards SAPIEN 3 Transcatheter Heart Valve$121
- ENTRESTO$111
- COBALT DR MRI SURESCAN$101
How this compares
$6,905 in reported general payments places this provider in the 65th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 701 | $688,471 |
| JardianceEmpagliflozin | 132 | $148,526 |
| XareltoRivaroxaban | 118 | $116,566 |
| MultaqDronedarone Hcl | 65 | $81,350 |
| EntrestoSacubitril/Valsartan | 49 | $69,304 |
| Repatha SureclickEvolocumab | 77 | $64,661 |
| OzempicSemaglutide | 32 | $29,940 |
| Metoprolol Succinate | 514 | $7,076 |
| Atorvastatin Calcium | 562 | $6,361 |
| Losartan Potassium | 446 | $4,456 |
| Nebivolol Hcl | 68 | $3,327 |
| Amlodipine Besylate | 376 | $2,923 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 84 | $2,445 |
| Ranolazine ErRanolazine | 22 | $2,423 |
| Ezetimibe | 94 | $2,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $474 | $688,471701 claims |
| Boehringer IngelheimJardiance | $54 | $148,526132 claims |
| Johnson & JohnsonXarelto | $13 | $116,566118 claims |
| Sanofi-aventis U.S. LLCMultaq | $46 | $81,35065 claims |
| NovartisEntresto | $233 | $69,30449 claims |
| Novo NordiskOzempic | $49 | $29,94032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Shreveport
- Anil ChhabraShreveport$1.9M
- William EavesShreveport$1.6M
- Wenwu ZhangShreveport$1.1M
- Neeraj TandonShreveport$53K
- Basel KasabaliShreveport$30K
- Ralph BaucumShreveport$29K
- Tina FirouzbakhtShreveport$28K
- Phillip RozemanShreveport$15K
- Jagan BeedupalliShreveport$13K
- Ghiath MikdadiHammond$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.